- Home
- AVIR vs OCGN Comparison
AVIR vs OCGN Comparison
Compare AVIR & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- OCGN
- Stock Information
- Founded
- AVIR 2012
- OCGN 2013
- Country
- AVIR United States
- OCGN United States
- Employees
- AVIR N/A
- OCGN N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVIR Health Care
- OCGN Health Care
- Exchange
- AVIR Nasdaq
- OCGN Nasdaq
- Market Cap
- AVIR 284.6M
- OCGN 229.2M
- IPO Year
- AVIR 2020
- OCGN N/A
- Fundamental
- Price
- AVIR $3.24
- OCGN $0.75
- Analyst Decision
- AVIR Hold
- OCGN Strong Buy
- Analyst Count
- AVIR 1
- OCGN 3
- Target Price
- AVIR $6.88
- OCGN $5.67
- AVG Volume (30 Days)
- AVIR 505.9K
- OCGN 6.4M
- Earning Date
- AVIR 02-26-2025
- OCGN 11-08-2024
- Dividend Yield
- AVIR N/A
- OCGN N/A
- EPS Growth
- AVIR N/A
- OCGN N/A
- EPS
- AVIR N/A
- OCGN N/A
- Revenue
- AVIR N/A
- OCGN $4,700,000.00
- Revenue This Year
- AVIR N/A
- OCGN N/A
- Revenue Next Year
- AVIR N/A
- OCGN N/A
- P/E Ratio
- AVIR N/A
- OCGN N/A
- Revenue Growth
- AVIR N/A
- OCGN N/A
- 52 Week Low
- AVIR $2.75
- OCGN $0.50
- 52 Week High
- AVIR $4.60
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- AVIR 47.81
- OCGN 41.68
- Support Level
- AVIR $3.11
- OCGN $0.70
- Resistance Level
- AVIR $3.49
- OCGN $1.00
- Average True Range (ATR)
- AVIR 0.14
- OCGN 0.07
- MACD
- AVIR -0.00
- OCGN -0.01
- Stochastic Oscillator
- AVIR 26.58
- OCGN 17.93
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").